Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Optimization of Voriconazole Therapy for the Treatment of Invasive Fungal Infections in Adults.

Clinical pharmacology and therapeutics - 1 Nov 2018

Mangal Naveen, Hamadeh Issam S, Arwood Meghan J, Cavallari Larisa H, Samant Tanay S, Klinker Kenneth P, Bulitta Jurgen, Schmidt Stephan

Abstract excerpt

Therapeutic concentrations of voriconazole in invasive fungal infections (IFIs) are ensured using a drug monitoring approach, which relies on attainment of steady-state pharmacokinetics. For voriconazole, time to reach steady state can vary from 5-7 days, not optimal for critically ill patients. We developed a population pharmacokinetic/pharmacodynamic model-based approach to predict doses that can maximize the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aspergillosis
Share to Aspergillus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Candida

Share to Drug Dosage Calculations

Share to Drug Monitoring

Share to Pharmacogenomic Variants

Share to Proton Pump Inhibitors

Share to Voriconazole

Source

Open in PubMed Open full text

Identifiers

PMID: 29315506
DOI: 10.1002/cpt.1012
PMCID: PMC6037619

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Optimization of Voriconazole Therapy for the Treatment of Invasive Fungal Infections in Adults.PMID 29315506Read ↗

Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections.Semantic proximity Read ↗

Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing.Semantic proximity Read ↗

Therapeutic drug monitoring of voriconazole.Semantic proximity Read ↗

Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy.Semantic proximity Read ↗

Evaluation of Voriconazole CYP2C19 Phenotype-Guided Dose Adjustments by Physiologically Based Pharmacokinetic Modeling.Semantic proximity Read ↗

Model-Oriented Dose Optimization of Voriconazole in Critically Ill Children.Semantic proximity Read ↗

Population Pharmacokinetics and Factors Influencing Trough Concentration of Voriconazole in Children with Hematological MalignanciesSemantic proximity Read ↗

Inflammation-driven variability in drug metabolism: Insights from voriconazole treatment of HSCT recipients.Semantic proximity Read ↗

Randomised multicentre clinical trial to evaluate voriconazole pre-emptive genotyping strategy in patients with risk of aspergillosis: vorigenipharm study protocol.Semantic proximity Read ↗

<i><scp>CYP</scp>2C19</i> Polymorphisms and Therapeutic Drug Monitoring of Voriconazole: Are We Ready for Clinical Implementation of Pharmacogenomics?Semantic proximity Read ↗

Population pharmacokinetics of voriconazole and CYP2C19 phenotype for dose optimization in hematological patients with invasive fungal infectionsSemantic proximity Read ↗

[CYP2C19 genetic polymorphism and monitoring voriconazole plasma concentrations in the treatment and prevention of invasive fungal disease for hematological patients].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.